Abstract
Multiple Sclerosis is the most common non-traumatic disorder of the central nervous system and is generally regarded as an immune-mediated disorder that occurs in young adults. Since cerebrospinal fluid is in close contact with the extracellular surface of the brain, it is of great interest to examine possible biomarkers for multiple sclerosis. Proteomic studies of cerebrospinal fluid samples represent an important step towards a better understanding of the disease and may lead to the identification of clinically useful markers. Methodological advances in proteomics allowed the comparison of the protein content in different cerebrospinal fluid samples, using gel or liquid-based approaches coupled with mass spectrometry. In this paper, we discuss the advantages and limitations of the strategies employed and the potential biomarkers for multiple sclerosis identified so far using proteomics-based approaches.
Keywords: Multiple sclerosis, cerebrospinal fluid, biomarkers, proteomics, inflammatory demyelinating disease, autoimmune aetiology, heterogeneity, inflammation, neuronal lesions, magnetic resonance imaging, neurodegenerative disorders, homeostasis, mass spectrometry, gel-free techniques, proteomics-based technologies
Current Molecular Medicine
Title: Proteomics-Based Technologies in the Discovery of Biomarkers for Multiple Sclerosis in the Cerebrospinal Fluid
Volume: 11 Issue: 4
Author(s): A. S.T. Lourenco, I. Baldeiras, M. Graos and C. B. Duarte
Affiliation:
Keywords: Multiple sclerosis, cerebrospinal fluid, biomarkers, proteomics, inflammatory demyelinating disease, autoimmune aetiology, heterogeneity, inflammation, neuronal lesions, magnetic resonance imaging, neurodegenerative disorders, homeostasis, mass spectrometry, gel-free techniques, proteomics-based technologies
Abstract: Multiple Sclerosis is the most common non-traumatic disorder of the central nervous system and is generally regarded as an immune-mediated disorder that occurs in young adults. Since cerebrospinal fluid is in close contact with the extracellular surface of the brain, it is of great interest to examine possible biomarkers for multiple sclerosis. Proteomic studies of cerebrospinal fluid samples represent an important step towards a better understanding of the disease and may lead to the identification of clinically useful markers. Methodological advances in proteomics allowed the comparison of the protein content in different cerebrospinal fluid samples, using gel or liquid-based approaches coupled with mass spectrometry. In this paper, we discuss the advantages and limitations of the strategies employed and the potential biomarkers for multiple sclerosis identified so far using proteomics-based approaches.
Export Options
About this article
Cite this article as:
S.T. Lourenco A., Baldeiras I., Graos M. and B. Duarte C., Proteomics-Based Technologies in the Discovery of Biomarkers for Multiple Sclerosis in the Cerebrospinal Fluid, Current Molecular Medicine 2011; 11 (4) . https://dx.doi.org/10.2174/156652411795677981
DOI https://dx.doi.org/10.2174/156652411795677981 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness
Current Neurovascular Research Conserved Domains, Residues, WebLogo and Active Sites of Caspase- Cascades Related to Apoptotic Signaling Pathway
Current Bioinformatics Cellular Toxicity of Mesoporous Silica Nanoparticle in SHSY5Y and BMMNCs Cell
Pharmaceutical Nanotechnology Fungal Gene-Encoded Peptidase Inhibitors
Current Medicinal Chemistry Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences
Current Pharmaceutical Design Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology Targeting Parkinson’s - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Microglia - A Therapeutic Target in Neurological Diseases and Disorders)
CNS & Neurological Disorders - Drug Targets Editorial
Recent Patents on Drug Delivery & Formulation Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry Acting Before; A Combined Strategy to Counteract the Onset and Progression of Dementia
Current Alzheimer Research Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Associations of Cerebrovascular and Alzheimer’s Disease Pathology with Brain Atrophy
Current Alzheimer Research Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Freezing of Gait in Parkinsonism and its Potential Drug Treatment
Current Neuropharmacology Alzheimer’s Disease Amyloid Peptides Interact with DNA, As Proved by Surface Plasmon Resonance
Current Alzheimer Research Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Potential Beneficial Effects of Marine Peptide on Human Neuron Health
Current Protein & Peptide Science